FDA-Approved Nivolumab and Ipilimumab for HCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Opdivo Prescribing Information. Opdivo U.S. Product Information. Last updated: March 2020. Princeton, NJ: Bristol Myers Squibb Company.
- Yervoy Prescribing Information. Yervoy U.S. Product Information. Last updated: March 2020. Princeton, NJ: Bristol Myers Squibb Company.
- National Comprehensive Cancer Network. Hepatobiloary Cancer (Version 4.2019). Accessed March 12, 2020.
- El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502.
- Yau T, Kang YK, Kim TY, et al. Nivolumab + Ipilimumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma: Results From CheckMate 040. J Clin Oncol. 2019;37(15_suppl):4012.
Disclosure statements are available on the authors' profiles: